A lawsuit was filed on behalf of investors in CorMedix Inc. (NYSEMKT:CRMD) shares over alleged securities laws violations and NYSEMKT:CRMD investors should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 07/20/2015 --An investor, who purchased shares of CorMedix Inc. (NYSEMKT:CRMD), filed a lawsuit over alleged violations of Federal Securities Laws by CorMedix Inc. in connection with certain allegedly false and misleading statements.

Shares of CorMedix Inc. (NYSEMKT:CRMD) declined on June 29, 2015, to as low as $3.62 per share., respectively $3.20 per share on July 2, 2015.

Investors who purchased shares of CorMedix Inc. (NYSEMKT:CRMD) have certain options and for certain investors are short and strict deadlines running. Deadline: September 4, 2015. NYSEMKT:CRMD investors should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of CorMedix Inc. (NYSEMKT:CRMD) common shares between March 12, 2011 and June 29, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 12, 2011 and June 29, 2015 defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose that: CorMedix Inc.'s announcements regarding its partnership discussions and imminent Phase 3 trials for its sole product, Neutrolin, were materially false and misleading, that clinical studies touted by CorMedix were misleading and overstated Neutrolin's effectiveness when in fact Neutrolin offers no benefit compared to current industry protocols, that CorMedix Inc. overstated the cost effectiveness of Neutrolin compared to currently established medical protocols, that CorMedix Inc.'s market claims for Neutrolin were overstated, that CorMedix Inc. stock achieved an unsustainable valuation by using paid stock promoters, yet failed to disclose the use of such promoters in its regulatory filings pursuant to Section 17(b) of the Securities Act of 1933, that CorMedix Inc. insiders enriched themselves at the expense of shareholders by selling stock at inflated prices, and that as a result of the foregoing, CorMedix's public statements were materially false and misleading at all relevant times.

Then on June 29, 2015,a report was published on CorMedix Inc asserting, among other things, that CorMedix Inc is based on a 1970s-era catheter product acquired for less than $1 million in a bankruptcy sale, apparently after at least two failed sales processes, that CorMedix's market size claims are greatly exaggerated, and that CorMedix Inc is touting misleading clinical-data, as in-depth industry research shows its Neutrolin/Taurolidine product is a failure and "40% benefit!" versus industry standards is inaccurate.

Those who purchased shares of CorMedix Inc. (NYSEMKT:CRMD) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com